



日本安全性薬理研究会

Japanese Safety Pharmacology Society

6th Japanese Safety Pharmacology Society (JSPS) Annual Meeting

Program (FINAL)

Date: February 20 (Fri) -21 (Sat), 2015

Venue: The University of Tokyo, Yayoi Auditorium, Ichijo Hall / Annex Seihoku Gallery

President: Mitsuyasu Tabo (Chugai Pharmaceutical Co., Ltd.)

Day 1 (February 20th)

10:00 - 17:00 **Poster Sessions** (Annex Seihoku Gallery)

9:50 - 10:00 **Opening**

Opening remarks (Mitsuyasu Tabo, President of 6th Annual Meeting)

10:00 - 11:50 **Symposium 1 [Cardiovascular system] (Yayoi Auditorium, Ichijo Hall)**

Moving from QT risk to the actual pro-arrhythmia risk evaluation

Moderator: Katsuyoshi Chiba (DAIICHI SANKYO CO., LTD.), Tomoharu Osada (LSI Medience Corp.)

1. Comprehensive *in vitro* cardiac safety assessment using human stem cell technology (CSAHi: HEART)
Kiyoshi Takasuna (Medicinal Safety Research Laboratories, DAIICHI SANKYO CO., LTD.)
2. *In silico* risk assessment of drug-induced arrhythmia using the multi-scale heart simulator 'UT-Heart'
Seiryu Sugiura (Graduate School of Frontier Sciences, The University of Tokyo)
3. Proarrhythmic risk assessment in preclinical and modeling approach in clinical pharmacology
Mikiko Nakamura (Clinical Research Planning Dept. Clinical Div., Chugai Pharmaceutical Co., Ltd.)

12:10 - 13:10 **Luncheon Seminar 1 (Faculty of Agriculture, building number 1st)**

1. Improvement of the cardiovascular evaluation in general toxicity study ~An approach using the JET system~
Junko Taketo, Ryuichi Komatsu (Research Division, Chugai Pharmaceutical Co., Ltd.)
(Sponsored by Primetech corporation)
2. Human iPS cell-derived tissue cells and applications for the drug discovery
Hideo Saotome (Product Development & Operations, iPS PORTAL, Inc.)
(Sponsored by iPS PORTAL, Inc.)

13:30 - 14:30 Educational Lecture (Yayoi Auditorium, Ichijo Hall)

Moderator: Mitsuyasu Tabo (Chugai Pharmaceutical Co., Ltd.)

Pharmacological research using stem cell-derived cardiac myocytes; From basic background to pharmaceutical applications

Junko Kurokawa (Dept. Bio-inform., Medical Research Institute, Tokyo Med. Dent. Univ.)

14:45 - 16:35 Oral Session (Yayoi Auditorium, Ichijo Hall)

Moderator: Hiroyuki Tashibu (Ina Research Inc.), Hiroyuki Ando (Ono Pharmaceutical Co., Ltd.)

1. Challenges in detection of premonitory electroencephalographic (EEG) changes of drug-induced seizure using a non-human primate EEG model
Motohiro Shiotani (Tsukuba Drug Safety, Global Drug Safety, Biopharmaceutical Assessments Core Function Unit, Eisai Co., Ltd.)
2. A subject NOT permitted to publish on Web program
3. Effects of class I antiarrhythmic drugs on the electrical excitation and conduction in the human iPS cell-derived cardiomyocyte sheet
Hiroko Izumi-Nakaseko (Department of Pharmacology, Faculty of Medicine, Toho University)
4. Multi-spheroid imaging analysis of human induced pluripotent stem cell-derived cardiomyocyte by Cellvoyager CV7000 system for the assessment of in vitro cardiotoxicity
Tadashi Nagakura (Global CV Assessment Unit, Tsukuba Research Laboratory, Eisai Co., Ltd.)

Moderator: Harushige Ozaki (Takeda Pharmaceutical Company Limited), Akihiro Kanno (Drug Safety Testing Center Co., Ltd.)

5. Utility of halothane-anesthetized guinea pig as a model to assess the drug-induced QT-interval prolongation: why can *dl*-sotalol prolong the QT interval in vivo despite its weak inhibitory effect on hERG K⁺ channels in vitro?
Jun Katagi (Department of Pharmacology, Faculty of Medicine, Toho University)
6. Apomorphine does NOT induce long QT syndrome: experimental evidence from in vivo canine models
Yudai Watanabe (Department of Pharmacology, Faculty of Medicine, Toho University)
7. Electropharmacological effects of a selective EP4-receptor stimulation by ONO-AE1-329 assessed by the halothane-anesthetized canine model
Hiroaki Nomura (Department of Pharmacology, Faculty of Medicine, Toho University)

16:50 - 17:50 Overseas Invited Speakers (Yayoi Auditorium, Ichijo Hall)

Moderator: Kohei Sawada (Eisai Co., Ltd.)

The cardiac in vitro proarrhythmia Initiative (CiPA): goals, progress, and paths forward

Gary Gintant (AbbVie Inc.)

18:30 -

Banquet Party (Sanjo Conference Hall)

Day 2 (February 21st)

9:00 - 15:00 **Poster Sessions** (Annex Seihoku Gallery)

Poster Discussion (11:00 - 12:20)

9:00 - 10:50 **Symposium 2 [Central nervous system] (Yayoi Auditorium, Ichijo Hall)**

Frontline of CNS research

Moderator: Seiji Hayashi (Nippon Shinyaku Co., Ltd.), Yoshiki Deguchi (Shin Nippon Biomedical Laboratories, Ltd.)

1. Optogenetics and pharmacogenetics to reveal regulatory mechanism of instinctive behaviors
Akihiro Yamanaka (Dept. Res. Inst. Env. Med., Nagoya Univ.)
2. Large-scaled network reorganization during recovery from partial spinal cord injury
Tadashi Isa (National Institute for Physiological Sciences)
3. Challenges towards stem cell therapy for Parkinson's disease
Jun Takahashi (Center for iPS Cell Research and Application, Kyoto University)

12:30 - 13:30 **Luncheon Seminar 2 (Faculty of Agriculture, building number 1st)**

1. Assessing cardiac liability using hiPS-derived Cor.4U cardiomyocytes in the xCELLigence RTCA Cardio and CardioECR
v Haniel F (Axiogenesis AG), Xiaoyu Z (ACEA Biosciences)
(Sponsored by Scrum Inc./ACEA Biosciences Inc.)
2. Evaluation of behavior in safety pharmacology: a way to translational research
Naoyuki Hironaka (Pharmacology Dept., Drug Development Service Segment, LSI Medience Corp.)
(Sponsored by LSI Medience Corp.)

14:00 - 15:30 **Workshop (Yayoi Auditorium, Ichijo Hall)**

Future vision of QT and pro-arrhythmia risk assessment in drug discovery

Moderator: Takashi Yoshinaga (Eisai Co., Ltd.), Yoshiko Okai (Takeda Pharmaceutical Co., Ltd.)

1. How should we practically use *in vitro/in silico* cardiac safety assessment for evaluating the pro-arrhythmia risk of new drugs?
Taeko Kubo (Preclinical Research Laboratories, Sumitomo Dainippon Pharma Co., Ltd.)
2. How to use *in vivo* ECG data and evaluate the pro-arrhythmia risk with *in vitro/silico* data in drug discovery?
Masaki Honda (Research Division, Chugai Pharmaceutical Co., Ltd.)
3. Panel Discussion

16:00 - 17:00 **Safety Pharmacology Q&A (Yayoi Auditorium, Ichijo Hall)**

Moderator: Chieko Kasai (Astellas Pharma Inc.), Hiroshi Yokoyama (Nippon Kayaku Co., Ltd.)

17:00 - **Closing (Yayoi Auditorium, Ichijo Hall)**

JSPS award ceremony (Mitsuyasu Tabo, Selection Chairman)

Closing remarks (Seiji Hayashi, President of 7th Annual Meeting)